MedTrace Logo

A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects

NCT03726866 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-11-01

No results posted yet for this study

Summary

To evaluate pharmacokinetic properties and drug interactions between D326 and D337 co-administered groups, the CKD-828 alone and the total co-administered groups.

Conditions

Interventions

DRUG

Sequence 1

D326, D337 or CKD-828 for 9 days

DRUG

Sequence 2

D326, D337 or CKD-828 for 9 days

DRUG

Sequence 3

D326, D337 or CKD-828 for 9 days

DRUG

Sequence 4

D326, D337 or CKD-828 for 9 days

DRUG

Sequence 5

D326, D337 or CKD-828 for 9 days

DRUG

Sequence 6

D326, D337 or CKD-828 for 9 days

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Hyeong-Seok Lim, M.D., Ph.D. · Department of Clinical Pharmacology and Therapeutics / Asan Medical Center, University of Ulsan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-31
Primary Completion
2019-01-15
Completion
2019-01-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03726866 on ClinicalTrials.gov